The Clinical, Technological, and Scientific Progress of Boron Neutron Capture Therapy

Dear Colleagues,

Boron neutron capture therapy (BNCT) has emerged as a clinically viable particle therapy, enabling tumor-selective irradiation based on molecular targeting. With the advent of accelerator-based neutron sources and advanced compound development, BNCT is now entering an era of practical medical application and broader social implementation. This Special Issue aims to collect cutting-edge research that accelerates the clinical, technological, and scientific progress of BNCT. We welcome studies from diverse disciplines, including physics, chemistry, biology, engineering, drug development, neutron dosimetry, and radiobiological effects. While boron-based approaches remain central, contributions exploring other neutron capture agents and novel concepts in neutron capture therapy (NCT) are also encouraged.

The purpose of this Special Issue is to present new insights into the expanding frontiers of BNCT and its future role in precision radiation oncology.

This Special Issue welcomes reviews as well as original research articles, which should be submitted by 15 September 2026.

Prof. Dr. Shinji Kawabata
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.